Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David M. Shapiro is active.

Publication


Featured researches published by David M. Shapiro.


The American Journal of the Medical Sciences | 2012

Viral Infections in Patients With Inflammatory Bowel Disease on Immunosuppressants

Tauseef Ali; Laura Yun; David M. Shapiro; Mohammad F. Madhoun; Michael S. Bronze

Abstract:The use of immunosuppressant medications and biologics such as tumor necrosis factor alpha antagonists has revolutionized the treatment of inflammatory bowel disease. With increasing use of such agents, the risk of serious infections is a key safety concern for treated patients. Greater physician awareness about these potential infections is important to optimize patient outcomes through early recognition and potential preventive strategies. The authors present a comprehensive and concise review of clinically important viral infections associated with the inflammatory bowel disease therapy.


World Journal of Gastroenterology | 2014

Hepatitis B vaccination in patients with inflammatory bowel disease

Ruwaida Ben Musa; Anuhya Gampa; Sanjib Basu; Ali Keshavarzian; Garth Swanson; Michael D. Brown; Rana Abraham; Keith Bruninga; John Losurdo; Mark T. DeMeo; Sohrab Mobarhan; David M. Shapiro; Ece Mutlu

AIM To determine the prevalence for hepatitis B virus (HBV) and HBV screening and vaccination practices for inflammatory bowel disease (IBD). METHODS This study is a retrospective, cross-sectional observational study. A retrospective chart review was performed in 500 patients who have been consecutively treated for IBD between September 2008 and January 2013 at the Rush University Medical Center Gastroenterology section. The patients were identified through the electronic medical record with the criteria that they attended the gastroenterology clinic, and that they had a diagnosis of IBD at the time of visit discharge. Once identified, each record was analyzed to determine whether the subject had been infected with HBV in the past, already been vaccinated against HBV, or advised to get vaccinated and followed through with the recommended vaccination. RESULTS About 254 out of 500 patients (51%) had HBV screening ordered. Among those ordered to have screening tests, 86% followed through with HBV serology. Gastroenterology physicians had significantly different screening ratios from each other (P < 0.001). There were no significant differences in the ratios of HBV screening when IBD specialists were compared to other gastroenterology physicians (0.505 ± 0.023 vs 0.536 ± 0.066, P = 0.66). Of those 220 patients screened, 51% of IBD patients were found not to be immune against HBV. Approximately 50% of gastroenterology physicians recommended HBV vaccinations to their patients in whom serology was negative for antibodies against HBV. IBD specialists recommended vaccinations to a higher percentage of their patients compared to other gastroenterology physicians (0.168 ± 0.019 vs 0.038 ± 0.026, P = 0.015). Present and/or past HBV infection was found in 3.6% of the patients who had serology checked. There was no statistically significant difference in the prevalence of hepatitis B surface antigen (HBsAg) between our study and that reported in previous studies done in Spain (4/220 vs 14/2076 respectively, P = 0.070); and in France (4/220 vs 3/315 respectively, P = 0.159). But, the prevalence of anti-HBcAb in this study was less than that reported in the study in Spain (7/220 vs 155/2076 respectively, P = 0.006); and was not significantly different from that reported in the study in France (7/220 vs 8/315 respectively, P = 0.313). CONCLUSION The prevalence of HBsAg in our IBD patients was not higher than previously reported European studies. Most IBD patients are not routinely screened or vaccinated against HBV at a tertiary referral center in the United States.


Diseases of The Esophagus | 2015

Negative surveillance endoscopy occurs frequently in patients with short-segment non-dysplastic Barrett's esophagus.

Joshua E. Melson; Vishal Desai; Michael Greenspan; S. Yau; M. Abdalla; R. Dhanekula; Sohrab Mobarhan; David M. Shapiro; John Losurdo; Shriram Jakate

Surveillance endoscopy of non-dysplastic Barretts esophagus (NDBE) that fails to detect intestinal metaplasia (IM), or negative surveillance, is known to occur in clinical practice, although the frequency and possible outcomes in a large cohort in clinical practice is not well described. The goals of this study were to define frequency in which negative surveillance occurs and endoscopic outcomes in a screening cohort of short segment NDBE. A retrospective cohort (n = 184) of patients newly diagnosed with short segment NDBE at an outpatient academic tertiary care center between 2003 and 2011 were reviewed. Only those with one or more surveillance endoscopies were included to define a frequency of negative surveillance. Included patients were further assessed if they had two or more surveillance endoscopies and were classified into groups as sampling error or negative IM on consecutive surveillances based on the results of their surveillance endoscopies. The frequency of a negative surveillance endoscopy in all short-segment NDBE patients was 19.66% (92 endoscopic exams were negative for IM of 468 total surveillance exams). A negative surveillance endoscopy occurred in 40.76% (n = 75) patients. Sampling error occurred in 44.12% and negative IM on consecutive surveillance endoscopies in 55.88% of those with ≥ 2 surveillance endoscopies and an initially negative surveillance exam. The frequency of negative IM on consecutive surveillances was 19.00% of all patients who had two surveillance endoscopies. When the index diagnostic Barretts esophagus segment length was < 1 cm, 32.14% (18/56) of all patients (with ≥ 2 surveillance endoscopies) had negative IM on consecutive surveillance endoscopies. Negative surveillance occurs frequently in short-segment NDBE. When an initial negative surveillance endoscopy occurs, it may be due to either a sampling error or lack of detectable IM on surveillance exam. When a <1 cm segment of NDBE is diagnosed, a significant proportion of patients may go on to have continuously undetected IM on consecutive surveillance endoscopic exams without intervention.


Digestive Endoscopy | 2014

Aneurysm of the portal vein confluence diagnosed by endoscopic ultrasound

Suhail B. Salem; A. Aziz Aadam; David M. Shapiro

tion with establishment of pneumothorax was selected. A long esophagomyotomy was created without perforation of the mucosa (Fig. 1b), as confirmed by intraoperative endoscopy. The total length of the myotomy was 15 cm, the operation took 138 min and blood loss was approximately 25 mL. The patient experienced no postoperative complications, and the symptoms related to jackhammer esophagus were considerably improved. The hypercontractile segment was not detectable by HRM after the operation (Fig. 2b). Thirty two months after the operation, the surgery was proven effective without the need for additional treatment. To our knowledge, this is the first report to describe successful surgical treatment, using thoracoscopic esophageal long myotomy in the prone position, for a patient with jackhammer esophagus.


Journal of Clinical Oncology | 2013

Efficacy and safety of venting percutaneous endoscopic gastrostomy (VPEG) tube placement in patients with malignant obstruction.

Rachel B. Issaka; David M. Shapiro; Mary F. Mulcahy; Srinadh Komanduri; John Martin; Neehar D. Parikh

538 Background: Refractory nausea and vomiting are common in patients with advanced malignancy. A venting percutaneous endoscopic gastrostomy (VPEG) tube can be placed to eliminate the need for a nasogastric tube and palliate obstructive symptoms. The aim of this study was to determine the outcomes of VPEG placement in patients with advanced malignancy. Methods: We retrospectively reviewed all patients in whom a VPEG tube was attempted for a malignant indication over a 13-year period (1998-2010). Demographic and clinical information, procedure details, and immediate & delayed complications were recorded. Results: Endoscopic VPEG placement was attempted in 96 patients (95% inpatient) with a median age of 57y. Colorectal (27%), pancreas (18.8%), and gynecologic (17.7%) malignancies were most common. Ascites was present in 46.9% of patients with drainage performed in a minority of patients (35.6%). VPEG was successfully placed by endoscopy in 89 patients (92.7%). Relief of obstructive symptoms was observed i...


Surgical Endoscopy and Other Interventional Techniques | 2014

Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction

Rachel B. Issaka; David M. Shapiro; Neehar D. Parikh; Mary F. Mulcahy; Srinadh Komanduri; John Martin


Archive | 2015

Lenient in Theory, Dumb in Fact: Prison, Speech, and Scrutiny

David M. Shapiro


Michigan Law Review, First Impressions | 2015

To Seek a Newer World: Prisoners’ Rights at the Frontier

David M. Shapiro


Archive | 2013

Management of Advanced Small Bowel Malignancies.

Shapiro Ds; Abhitabh Patil; Melson Jm; David M. Shapiro


Gastrointestinal Endoscopy in the Cancer Patient | 2013

The Role of Endoscopy in Small Bowel Malignancies

David M. Shapiro; Joshua E. Melson; Abhitabh Patil

Collaboration


Dive into the David M. Shapiro's collaboration.

Top Co-Authors

Avatar

John Martin

Northwestern University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Abhitabh Patil

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

John Losurdo

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Joshua E. Melson

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sohrab Mobarhan

Loyola University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge